ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms

Oncogenic ALK fusions occur in several types of cancer and can be effectively treated with ALK inhibitors; however, ALK fusions and treatment response have not been characterized in malignant melanomas. Recently, a novel isoform of ALK (ALK(ATI)) was reported in 11% of melanomas but the response of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Couts, Kasey L., Bemis, Judson, Turner, Jacqueline A., Bagby, Stacey M., Murphy, Danielle, Christiansen, Jason, Hintzsche, Jennifer D., Le, Anh, Pitts, Todd M., Wells, Keith, Applegate, Allison, Amato, Carol, Multani, Pratik, Chow-Maneval, Edna, Tentler, John J., Shellman, Yiqun G., Rioth, Matthew J., Tan, Aik-Choon, Gonzalez, Rene, Medina, Theresa, Doebele, Robert C., Robinson, William A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5752582/
https://ncbi.nlm.nih.gov/pubmed/29054983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0472
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia